Cell and Gene Outsourcing
-
How To Promote Batch-To-Batch Consistency In CAR-T Therapies
3/18/2024
Patient immune cells and varied raw materials introduce inherent biological variability into CAR-T therapy manufacturing, making it a constant balancing act of adjusting processes and technology to minimize batch-to-batch variability.
-
Spent Media Analysis To Improve Cell Therapy Manufacturing
3/14/2024
Targeted metabolomics-based PAT allows for metabolic profiling of the T-cells throughout the cell therapy manufacturing process through spent media analysis.
-
AAV cGMP Manufacturing Located In San Sebastian, Spain
3/13/2024
Viralgen's AAV manufacturing services are powered by the advanced Pro10™ platform, which has produced over 1000 successful batches of high-quality vectors crucial for gene therapy research.
-
CTDMO Services To Fast-Track The Advancement Of mRNA-Based Drugs
3/13/2024
Discover CTDMO services that establish robust, integrated, and consistent processes across all stages, enabling you to fast-track the advancement of your mRNA-based vaccines and therapeutics.
-
A CDMO’s Checklist For Prospective Clients
3/13/2024
In the last entry of our client checklist series, we delve into crucial aspects such as project management, decision-making, MSA negotiations, and building trust in CDMO-client partnerships.
-
A CDMO’s Checklist For Prospective Clients: Part 2
3/13/2024
In Part 2 of our series, we delve deeper into the crucial elements of transparency that prospective clients should consider when partnering with a CDMO, including analytics, documentation, and more.
-
A CDMO’s Checklist For Prospective Clients: Part 1
3/13/2024
Ever wondered about the flip side of client-CDMO dynamics? In this series, discover why transparency is vital for both parties in a fruitful partnership.
-
TAAV And Viralgen Together As Your rAAV Manufacturing Solution
3/13/2024
We significantly accelerate your program to cGMP by utilizing rapidly manufactured neDNA™ within the established Pro10™ production platform.
-
A Mammalian Suspension Technology For Scalable rAAV Production
3/13/2024
Explore a HEK293 derived animal component-free suspension cell line as the foundation of an up to 2000-liters scalable and robust platform process that increases the speed of AAV manufacturing.
-
Opportunities And Pain Points For CGT Innovation And Market Access
3/11/2024
Review key insights shared by experts during Advanced Therapies Week 2024 and explore what these mean in the broader context of successfully bringing cell and gene therapies to patients.